S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q1 2025

Baker Bros Advisors

Period: Q1 2025 Β· Filed: 2025-05-15
View on SEC EDGAR β†—
AUM
$9.04B
Total portfolio value
Positions
89
Reported securities
Top Holding
ONC
26.5% $2.39B
QoQ Changes
+4 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-05-15) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ONCBeiGene, Ltd.$2.39B26.50%$272.17$297.65+9.4%
26.5%
INCYIncyte Corporation$1.86B20.60%$60.55$116.86+93.0%
20.6%
ACADACADIA Pharmaceuticals Inc.$712.2M7.88%$16.61$25.97+56.4%
7.9%
MDGLMadrigal Pharmaceuticals, Inc.$654.0M7.24%$331.23$528.10+59.4%
7.2%
SMMTSummit Therapeutics Inc.$471.2M5.21%$19.29$15.42-20.1%
5.2%
INSMInsmed Incorporated$410.5M4.54%$76.29$111.60+46.3%
4.5%
RYTMRhythm Pharmaceuticals, Inc.$296.9M3.29%$52.97$114.17+115.5%
3.3%
RVMDRevolution Medicines, Inc.$280.6M3.11%$35.36$189.24+435.2%
3.1%
KYMRKymera Therapeutics, Inc.$164.1M1.82%$27.37$113.51+314.7%
1.8%
ALKSAlkermes plc$148.0M1.64%$33.02$54.58+65.3%
1.6%
EWTXEdgewise Therapeutics, Inc.$135.4M1.50%$22.00$39.56+79.8%
1.5%
REPLReplimune Group, Inc.$107.7M1.19%$9.75$11.58+18.8%
1.2%
Insmed Incorporated$101.6M1.12%β€”β€”
1.1%
IMVTImmunovant, Inc.$93.3M1.03%$17.09$38.79+127.0%
1.0%
BCYCBicycle Therapeutics plc$92.4M1.02%$8.49$4.35-48.8%
1.0%
IMCRImmunocore Holdings plc$68.9M0.76%$29.67$32.50+9.5%
0.8%
KNSAKiniksa Pharmaceuticals International, plc$62.6M0.69%$22.21$64.53+190.5%
0.7%
ABCLAbCellera Biologics Inc.$61.4M0.68%$2.23$8.11+263.7%
0.7%
RAREUltragenyx Pharmaceutical Inc.$57.1M0.63%$36.21$33.47-7.6%
0.6%
DNLIDenali Therapeutics Inc.$50.7M0.56%$13.60$25.83+89.9%
0.6%
KODKodiak Sciences Inc.$48.6M0.54%$2.81$38.54+1271.5%
0.5%
NRIXNurix Therapeutics, Inc.$46.1M0.51%$11.88$23.97+101.8%
0.5%
ARGXargenx SE$46.0M0.51%$591.86$939.68+58.8%
0.5%
TRDAEntrada Therapeutics, Inc.$44.0M0.49%$9.04$7.72-14.6%
0.5%
CELCCelcuity Inc.$43.0M0.48%$10.11$107.95+967.8%
0.5%
GRALGRAIL, Inc.$41.6M0.46%$25.54$69.11+170.6%
0.5%
ROIVRoivant Sciences Ltd.$38.0M0.42%$10.09$35.13+248.2%
0.4%
IMTXImmatics N.V.$32.8M0.36%$4.51$9.95+120.6%
0.4%
STOKStoke Therapeutics, Inc.$30.8M0.34%$6.65$32.70+391.7%
0.3%
CERSCerus Corporation$26.9M0.30%$1.39$3.16+127.3%
0.3%

Quarter-on-Quarter Activity

Q1 2025 vs. Q4 2024

New Positions (4)

TickerIssuerNotional
VRNAVerona Pharma plc$14.2M
RGLSRegulus Therapeutics Inc.$4.7M
SIONSionna Therapeutics, Inc.$4.2M
TECXTectonic Therapeutic, Inc.$1.8M

Exited Positions (8)

TickerIssuerNotional
Ionis Pharmaceuticals, Inc.$29.5M
KRYSKrystal Biotech, Inc.$26.6M
MIRMMirum Pharmaceuticals, Inc.$7.9M
ARVNArvinas, Inc.$7.8M
BMEABiomea Fusion, Inc.$5.6M
ARCTArcturus Therapeutics Holdings Inc.$2.6M
MRSNMersana Therapeutics, Inc.$1.6M
PTCTPTC Therapeutics, Inc.$0.9M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
PCVXVaxcyte, Inc.$20.2M+1211.0%
RCKTRocket Pharmaceuticals, Inc.$6.1M+1030.1%
IMVTImmunovant, Inc.$51.0M+219.6%+127.0%
NGNENeurogene Inc.$2.0M+120.4%
CELCCelcuity Inc.$8.0M+59.0%+967.8%
IMCRImmunocore Holdings plc$24.2M+53.3%+9.5%
INSMInsmed Incorporated$64.8M+7.5%+46.3%
ALKSAlkermes plc$27.8M+7.2%+65.3%

Trimmed (8)

TickerIssuerNotionalShares Ξ”
IPSCCentury Therapeutics, Inc.$-0.7M-69.7%
CYPHLeap Therapeutics, Inc.$-3.3M-65.5%
XENEXenon Pharmaceuticals Inc.$-27.3M-65.0%
CMPXCompass Therapeutics, Inc.$-1.2M-64.9%
ACRVAcrivon Therapeutics, Inc.$-0.3M-56.9%
MRUSMerus N.V.$-9.5M-50.3%
CRSPCRISPR Therapeutics AG$-29.2M-50.0%
AKROAkero Therapeutics, Inc.$-8.3M-50.0%
← Back to Hedge Funds